Terns Pharmaceuticals, Inc. Additional Paid in Capital
Terns Pharmaceuticals, Inc. had Additional Paid in Capital of $1.52 billion as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-03-30
- 2025-12-31: Additional Paid in Capital $1.52B.
- 2025-09-30: Additional Paid in Capital $778.07M.
- 2025-06-30: Additional Paid in Capital $774.72M.
- 2025-03-31: Additional Paid in Capital $771.37M.
| Period end | Additional Paid in Capital |
|---|---|
| 2025-12-31 | $1.52B 10-K · filed 2026-03-30 |
| 2025-09-30 | $778.07M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $774.72M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $771.37M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $767.62M 10-K · filed 2026-03-30 |
| 2024-09-30 | $763.98M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $596.85M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $592.04M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $588.01M 10-K · filed 2025-03-20 |
| 2023-09-30 | $570.86M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $556.76M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $552.04M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $520.18M 10-K · filed 2024-03-14 |
| 2022-09-30 | $411.63M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $348.23M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $345.45M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $342.71M 10-K · filed 2023-03-27 |
| 2021-09-30 | $340.14M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $337.49M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $335.48M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $14.60M 10-K · filed 2022-03-07 |